Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.046 AUD | +2.22% | +2.22% | -37.84% |
Feb. 29 | Radiopharm Theranostics Doses First Patient in Pancreatic Cancer Imaging Study | MT |
Feb. 29 | Radiopharm Theranostics Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 13.19M 20.16M |
---|---|---|---|---|---|
Net income 2024 * | -29M -44.31M | Net income 2025 * | -31M -47.37M | EV / Sales 2024 * | - |
Net Debt 2024 * | 5.28M 8.06M | Net Debt 2025 * | 3.96M 6.05M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.42
x | P/E ratio 2025 * |
-0.42
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 73.94% |
1 day | +2.22% | ||
1 week | +2.22% | ||
Current month | -17.86% | ||
1 month | -19.30% | ||
3 months | -35.21% | ||
6 months | -56.19% | ||
Current year | -37.84% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | - | 21-09-12 | |
Antje Wegener
CTO | Chief Tech/Sci/R&D Officer | - | - |
Gitasha Chand
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Hopper
CHM | Chairman | 68 | 21-02-10 |
Leila Alland
BRD | Director/Board Member | 61 | 22-06-05 |
Chief Executive Officer | - | 21-09-12 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 0.046 | +2.22% | 671 125 |
24-04-24 | 0.045 | -2.17% | 540,689 |
24-04-23 | 0.046 | +4.55% | 833,031 |
24-04-22 | 0.044 | -2.22% | 570,857 |
24-04-19 | 0.045 | 0.00% | 602,878 |
Delayed Quote Australian S.E., April 26, 2024 at 02:10 am EDT
More quotesEPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-37.84% | 13.22M | |
+24.35% | 653B | |
+25.58% | 556B | |
-6.33% | 354B | |
+19.90% | 331B | |
+7.95% | 296B | |
+12.84% | 233B | |
+5.11% | 201B | |
-9.94% | 193B | |
-6.47% | 144B |
- Stock Market
- Equities
- RAD Stock